Browse News
Filter News
Found 561,543 articles
-
TREVENA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Trevena, Inc. - TRVN
7/20/2019
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Trevena, Inc. (NasdaqGS: TRVN).
-
Gilead Snaps up Antiviral Programs From Novartis, Follows Slew of Other Pipeline-Bolstering Deals
7/19/2019
In addition to the three preclinical assets from Novartis, Gilead has recently entered into deals to develop therapies for HIV, RA and NASH. -
It was a big week for Alzheimer’s research as researchers from around the world descended on Los Angeles to attend the Alzheimer’s Association International Conference (AAIC) this week. Here's a look at some of the stories you may have missed.
-
A three-judge panel ruled against Shkreli's appeals team, claiming that the trial judge's directions were clear and within the law.
-
In its third installment of the Good Pharma Scorecard, Roche and Novo Nordisk scored perfect marks in overall trial transparency, while Johnson & Johnson slipped from the high spot on the previous ranking.
-
BioSpace Movers and Shakers, July 19
7/19/2019
Pharma and biotech companies from across the globe expand their leadership teams and boards. -
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Acacia's founder will continue on in an advisory role while ViiV's departing CSO is eying multiple opportunities.
-
There’s clearly a need for new antibiotics to fight infections. If so, why are so many companies in the space abandoning it or going out of business?
-
This week has marked a number of stories over construction projects and real estate developers focused on the life sciences market. Here’s a look.
-
Novartis Chief Executive Officer Vas Narasimhan is excited about the company’s progress through the first half of 2019 and expects that momentum to continue with a “catalyst-rich” second half of the year.
-
Top 5 Vendors in the Global Molecular Biology Enzymes, Kits, and Reagents Market 2019-2023 | Technavio
7/19/2019
High incidence of chronic diseases globally and the need for personalized medicine, has encouraged several technological advancements in the form of recombinant DNA that involves genetic combinations of species to treat diseases.
-
Bayer statement on voluntary recall of two lots of Kogenate® FS antihemophilic factor (recombinant) in the United States
7/19/2019
Bayer is voluntarily recalling two lots of Kogenate® FS antihemophilic factor (recombinant) 2000 IU vials in the United States to the patient level.
-
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease
7/19/2019
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
-
Trillium Community Health Plan Appoints Christopher Hummer To CEO
7/19/2019
Trillium Community Health Plan (Trillium) is pleased to announce the appointment of Christopher Hummer as the new CEO of Trillium and Health Net of Oregon, effective August 12, 2019.
-
FDA Accepts and Files 22nd Century Group’s Modified Risk Tobacco Product Application for VLN™ Cigarettes
7/19/2019
22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a world leader in tobacco harm reduction, announced today that the U.S. Food and Drug Administration (FDA) accepted and filed for substantive scientific review the Company’s Modified Risk Tobacco Product (MRTP) application for its exclusive Very Low Nicotine Content (VLNC) cigarettes under the proposed brand name of VLNTM
-
Statement from Health Canada on the supply of EpiPen 0.3 mg auto-injectors
7/19/2019
Health Canada is aware that Pfizer Canada is reporting that a shortage of its 0.3 mg format EpiPen auto-injector may lead to temporary supply constraints in the coming months. EpiPen Jr (0.15 mg) is not affected by this shortage.
-
Rising Pharmaceuticals Announces the U.S. Launch of a Generic Version of Pregabalin Capsules
7/19/2019
Rising Pharmaceuticals, a Rising Pharma Holdings Inc. company, today announced the U.S. launch & commercial shipment of a generic version of Lyrica®, (pregabalin) Capsules, in all eight commercially available strengths (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, & 300 mg.
-
Global Healthy Living Foundation Urges Presidential Candidates to Support the Rescheduling of Marijuana to Improve Access by Chronic Disease Patients
7/19/2019
The Global Healthy Living Foundation urges 2020 Presidential candidates to support the rescheduling of marijuana so that it, along with CBD products, can be tested under controlled parameters and with peer review to assess their safety, dosing, and effectiveness, arming both patients and doctors with the best available evidence to make informed treatment decisions
-
More women using cannabis daily before and during pregnancy, Kaiser Permanente research finds
7/19/2019
The number of women using cannabis in the year before they get pregnant and early in their pregnancies is increasing, and their frequency of use is also rising, according to new data from Kaiser Permanente.